Novo launches Ozempic and Fiasp in U.S.

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) launched in the U.S. Ozempic semaglutide (NN9535) to treat Type II diabetes

Read the full 172 word article

User Sign In